Xenetic Biosciences is a biopharmaceutical company. Co.'s drug candidates pipeline include: XCART, which is a CAR T cell platform technology engineered to target patient-specific tumor neoantigens; ErepoXen (polysialylated erythropoietin), which uses Co.'s PolyXen platform technology for the treatment of anemia in chronic kidney disease patients; XBIO-101, which is an internal candidate with orphan drug designation from the U.S. Food and Drug Administration for the potential treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy; and OncoHist, which utilizes the properties of modified human histone H1.3 for targeted cell killing. The XBIO average annual return since 2016 is shown above.
The Average Annual Return on the XBIO average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether XBIO average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the XBIO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|